Results 31 to 40 of about 2,272 (175)

Combating resistant pathogens: exploring the efficacy of eravacycline utilization in multidrug-resistant infections [PDF]

Microbiology Spectrum
Eravacycline, FDA-approved for complicated intra-abdominal infections, is increasingly used off-label for multidrug-resistant infections, including carbapenem-resistant Enterobacterales, Stenotrophomonas maltophilia, and carbapenem-resistant ...
Kiara Patino, Ryan Vathy, Ben Albrecht, Sujit Suchindran, Sarah B. Green   +4 more
doaj   +2 more sources

In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China [PDF]

Frontiers in Microbiology
IntroductionEravacycline (ERV), a novel tetracycline derivative, exhibits broad-spectrum antibacterial activity, but data on the bacterial activity against Chinese bacterial isolates are very scarce.
Xiaoyan Liao, Qianwen Liang, Xinlu Dai, Shigang Wu, Chaohui Duan, Zhaofan Luo, Xiaoying Xie   +6 more
doaj   +2 more sources

Comparative efficacy of eravacycline and tigecycline in addressing multidrug-resistant Gram-negative bacteria

One Health Advances
The rise in antibiotic resistance among Gram-negative bacteria poses significant challenges to global health. This study evaluates the in vitro efficacy of tigecycline, omadacycline, and eravacycline against clinical isolates harboring the mobile ...
Jing Zhang, Hanyu Wang, Aoxiao Chen, Ning Dong, Hongwei Zhou, Kewei Li   +5 more
doaj   +2 more sources

Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer. [PDF]

Int J Cancer
Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Ablinger C, Huber-Cantonati P, Weber DD, Pichler S, Schischkow G, Garcia-Miralles M, Pirich C, Rendl G, Kiener T, Felder T, Geroldinger M, Terkola R, Kofler B, Pachmayr J.   +13 more
europepmc   +2 more sources

Eravacycline: Data Based on Real Evidence.

The new microbiologica
Eravacycline, a novel synthetic fluorocycline, exhibits broad-spectrum antimicrobial activity against multidrug-resistant (MDR) Gram-positive, Gram-negative, and anaerobic bacteria, making it a promising option for complicated intra-abdominal infections (cIAI).
Giuliano, S, Martini, L, Prataviera, F, Moreal, C, Flammini, Sarah, Terrosu, G, De Cecchis, L, Lazzarotto, D, Zhanel, GG, Tascini, C   +9 more
core   +4 more sources

Eravacycline, a newly approved fluorocycline [PDF]

European Journal of Clinical Microbiology & Infectious Diseases, 2019
Complicated intra-abdominal infections (cIAIs) are commonly associated with multimicroorganisms and treatment choices are becoming narrower due to developing resistance, especially in the gram-negative Enterobacteriaceae species. Eravacycline is a newly developed, fully synthetic tetracycline derivative that has shown potent broad-spectrum activity ...
Young Ran Lee, Caitlin Elizabeth Burton
  +12 more sources

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source

The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis

Frontiers in Medicine, 2022
BackgroundEravacycline is a novel, fully synthetic fluorocycline antibiotic for the treatment of adults with complicated intra-abdominal infections (cIAIs).
Rui Meng, Rui Meng, Xin Guan, Xin Guan, Lei Sun, Lei Sun, Zhengyang Fei, Zhengyang Fei, Yuxin Li, Yuxin Li, Mengjie Luo, Mengjie Luo, Aixia Ma, Aixia Ma, Hongchao Li, Hongchao Li   +15 more
doaj   +1 more source

In Vitro Activity of Eravacycline and Comparator Agents Against Bacterial Pathogens Isolated From Patients With Cancer [PDF]

, 2023
BACKGROUND: Bacterial infections are common in patients with cancer, and many bacteria have developed resistance to currently used antibiotics. OBJECTIVES: We evaluated the METHODS: Antimicrobial susceptibility testing was performed using CLSI-approved ...
Nesher, Lior, Prince, Randall, Shelburne, Samuel A, Gerges, Bahgat, Rolston, Kenneth, Raad, Issam   +5 more
core   +1 more source

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates

Frontiers in Microbiology, 2022
In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus
Weiliang Zeng, Xiaotuan Zhang, Yan Liu, Yi Zhang, Mengxin Xu, Sipei Wang, Yao Sun, Tieli Zhou, Lijiang Chen   +8 more
doaj   +1 more source